Nexvet's pipeline product ranevetmab, a mAb targeting nerve-growth factor for treatment of chronic pain associated with osteoarthritis in dogs, would, upon approval, be the companion animal industry's first
monoclonal antibody therapy administered monthly by injection for chronic pain.
2,3 Erenumab is the first fully human
monoclonal antibody therapy specifically designed to target and block the Calcitonin Gene-Related Peptide (CGRP) receptor, believed to play a critical role in mediating the incapacitating pain of migraine.
M2 PHARMA-April 11, 2017-US FDA Grants Orphan Drug Designation for NantCell's Ganitumab
Monoclonal Antibody Therapy in Ewing Sarcoma
Filings: XBiotech has been granted Fast Track Designation for its novel True Human
monoclonal antibody therapy intended to treat all forms of Staphylococcus aureus infections, including Methicillin-resistant S.
Aratana Therapeutics has a full license from USDA for its
monoclonal antibody therapy called AT-004, intended for dogs with B-cell lymphoma.
Washington, September 2 ( ANI ): A
monoclonal antibody therapy developed by MassBiologics of the University of Massachusetts Medical School (UMMS) and tested in an animal model at the Texas Biomedical Research Institute, prevents infection by the hepatitis C virus (HCV).
This pocket guide aimed at oncologists, physicians, and nurses offers information in a bulleted format on diagnosis, surgery, and radiotherapeutic and chemotherapeutic treatment of breast cancer, including staging,
monoclonal antibody therapy, genetic aspects, and prevention.
Targeted anti-interleukin-6
monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
Managing drug infusion reactions: Focus on cetuximab
monoclonal antibody therapy.
It is controversial in that it is very expensive; it is only used in patients who have early HER2-positive disease; it has side-effects; and the long-term effects of
monoclonal antibody therapy are not known.
The scientific article, "CD32B, the Human Inhibitory Fc Receptor IIB, as a Target for
Monoclonal Antibody Therapy of B-Cell Lymphoma," appears in the October 2006 issue of Blood, the journal of the American Society of Hematology.
There is potential for a better overall response when these agents are combined with
monoclonal antibody therapy (e.
